consenso histoplasmose
19 pág.

consenso histoplasmose


DisciplinaInfectologia1.229 materiais6.916 seguidores
Pré-visualização13 páginas
John R. Graybill for their thoughtful reviews of
earlier drafts of the manuscript. The panel also wishes to thank Dr. Stanley
C. Deresinski for his guidance throughout the guideline development
process.
Financial support. The Infectious Diseases Society of America.
Potential conflicts of interest. L.J.W. is President of MiraVista Diag-
nostics and MiraBella Technologies; he has research contracts with Astellas,
Basilea, Schering-Plough, and Bio-Rad Laboratories and serves as a con-
sultant to Bio-Rad Laboratories; L.J.W. is also a speaker for Bio-Rad and
Enzon. J.W.B. has received research grants from Merck and Astellas and
is on the speakers\u2019 bureaus for Merck, Pfizer, and Enzon. A.G.F. serves as
a consultant for Enzon and as a speaker for Pfizer, Merck, and Schering.
C.A.K. has received research grants from Merck, Astellas, and Schering-
Plough and is on the speakers\u2019 bureaus for Merck, Pfizer, Astellas, and
Schering-Plough. D.S.M. is on the speakers\u2019 bureaus of Merck and Pfizer.
M.B.K. and J.E.L.: no conflicts.
APPENDIX A.
EXPERT PANEL
Infectious diseases: L. Joseph Wheat (MiraVista Diagnostics,
Indianapolis, IN), John W. Baddley (University of Alabama at
Birmingham and Birmingham Veterans Affairs Medical Cen-
ter), Alison G. Freifeld (University of Nebraska Medical Center,
Omaha), Carol A. Kauffman (University of Michigan and Vet-
erans Affairs Healthcare System, Ann Arbor), and David S.
McKinsey (ID Associates of Kansas City, Kansas City, MO).
Pediatric infectious diseases: Martin B. Kleiman (Indiana Uni-
versity School of Medicine, Indianapolis). Pulmonology: James
E. Loyd (Vanderbilt University Medical Center, Nashville, TN)
References
1. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the
management of patients with histoplasmosis. Infectious Diseases So-
ciety of America. Clin Infect Dis 2000; 30:688\u201395.
2. Field MJ, Lohr KN, eds; Institute of Medicine Committee to Advise
the Public Health Service on Clinical Practice Guidelines. Clinical
practice guidelines: directions for a new program. Washington, DC:
National Academy Press, 1990:55\u201377.
3. Canadian Task Force on the Periodic Health Examination. The pe-
riodic health examination. CMAJ 1979; 121:1193\u2013254.
4. Wheat LJ, Conces D, Allen SD, Blue-Hnidy D, Loyd J. Pulmonary
histoplasmosis syndromes: recognition, diagnosis, and management.
Semin Respir Crit Care Med 2004; 25:129\u201344.
5. Oliver A, Ciulla TA, Comer GM. New and classic insights into pre-
sumed ocular histoplasmosis syndrome and its treatment. Curr Opin
Ophthalmol 2005; 16:160\u20135.
6. Giles CL, Falls HF. Amphotericin B therapy in the treatment of pre-
sumed histoplasma chorioretinitis: a further appraisal. Am J Ophthal-
mol 1968; 66:101\u20134.
7. Sarosi GA, Voth DW, Dahl BA, Doto IL, Tosh FE. Disseminated his-
toplasmosis: results of long-term follow-up: a Center for Disease Con-
trol cooperative mycoses study. Ann Intern Med 1971; 75:511\u20136.
8. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of li-
posomal amphotericin B compared with conventional amphotericin
B for induction therapy of histoplasmosis in patients with AIDS. Ann
Intern Med 2002; 137:105\u20139.
9. Perfect JR. Treatment of non-Aspergillus moulds in immunocompro-
mised patients, with amphotericin B lipid complex. Clin Infect Dis
2005; 40(Suppl 6):S401\u20138.
10. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy
for blastomycosis and histoplasmosis. NIAID Mycoses Study Group.
Am J Med 1992; 93:489\u201397.
11. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of dis-
seminated histoplasmosis in patients with the acquired immunode-
ficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995; 98:
336\u201342.
12. Kohler S, Wheat LJ, Connolly P, et al. Comparison of the echinocandin
caspofungin with amphotericin B for treatment of histoplasmosis fol-
lowing pulmonary challenge in a murine model. Antimicrob Agents
Chemother 2000; 44:1850\u20134.
13. Graybill JR, Najvar LK, Montalbo EM, Barchiesi FJ, Luther MF, Rin-
aldi MG. Treatment of histoplasmosis with MK-991 (L-743,872). An-
timicrob Agents Chemother 1998; 42:151\u20133.
14. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole
SCH56592 and the echinocandins MK-0991 (L-743,872) and
LY303366 against opportunistic filamentous and dimorphic fungi and
yeasts. J Clin Microbiol 1998; 36:2950\u20136.
15. McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy
for histoplasmosis. The National Institute of Allergy and Infectious
Diseases Mycoses Study Group. Clin Infect Dis 1996; 23:996\u20131001.
16. Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis
with fluconazole in patients with acquired immunodeficiency syn-
drome. National Institute of Allergy and Infectious Diseases Acquired
Immunodeficiency Syndrome Clinical Trials Group and Mycoses
Study Group. Am J Med 1997; 103:223\u201332.
17. Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner R. Emer-
gence of resistance to fluconazole as a cause of failure during treatment
of histoplasmosis in patients with acquired immunodeficiency disease
syndrome. Clin Infect Dis 2001; 33:1910\u20133.
18. Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles
against Histoplasma capsulatum from patients with AIDS who failed
fluconazole. J Antimicrob Chemother 2006; 57:1235\u20139.
19. Connolly P, Wheat LJ, Schnizlein-Bick C, et al. Comparison of a new
triazole, posaconazole, with itraconazole and amphotericin B for treat-
ment of histoplasmosis following pulmonary challenge in immuno-
compromised mice. Antimicrob Agents Chemother 2000; 44:2604\u20138.
20. Al-Agha OM, Mooty M, Salarieh A. A 43-year-old woman with ac-
quired immunodeficiency syndrome and fever of undetermined or-
igin: disseminated histoplasmosis. Arch Pathol Lab Med 2006; 130:
120\u20133.
21. Hott JS, Horn E, Sonntag VK, Coons SW, Shetter A. Intramedullary
824 \u2022 CID 2007:45 (1 October) \u2022 Wheat et al.
histoplasmosis spinal cord abscess in a nonendemic region: case report
and review of the literature. J Spinal Disord Tech 2003; 16:212\u20135.
22. Freifeld AG, Iwen PC, Lesiak BL, Gilroy RK, Stevens RB, Kalil AC.
Histoplasmosis in solid organ transplant recipients at a large Mid-
western university transplant center. Transpl Infect Dis 2005; 7:
109\u201315.
23. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL,
Humar A. Fungal infections in transplant recipients receiving alem-
tuzumab. Transplant Proc 2005; 37:934\u20136.
24. Truong MT, Sabloff BS, Munden RF, Erasmus JJ. A patient with new-
onset seizure and mediastinal adenopathy. Chest 2004; 126:982\u20135.
25. Restrepo A, Tobon A, Clark B, et al. Salvage treatment of histoplas-
mosis with posaconazole. J Infect 2007; 54:319\u201327.
26. Clark B, Foster R, Tunbridge A, Green S. A case of disseminated
histoplasmosis successfully treated with the investigational drug po-
saconazole. J Infect 2005; 51:e177\u201380.
27. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole
in the treatment of central nervous system fungal infections. J An-
timicrob Chemother 2005; 56:745\u201355.
28. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using
target drug concentrations. Clin Pharmacokinet 1998; 35:461\u201373.
29. Hecht FM, Wheat J, Korzun AH, et al. Itraconazole maintenance
treatment for histoplasmosis in AIDS: a prospective, multicenter trial.
J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:100\u20137.
30. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T,
Schmidt-Wolf IG. Itraconazole through concentrations in antifungal
prophylaxis with six different dosing regimens using hydroxypropyl-
beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses
1999; 42:591\u2013600.
31. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug
monitoring. Antimicrob Agents Chemother 2006; 50:1570\u20132.
32. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole,
a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br
J Clin Pharmacol 2003; 56(Suppl 1):10\u20136.
33. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics,